What class is Stivarga (regorafenib) in?
Stivarga (regorafenib) is an oral cancer medicine that belongs to the class of drugs called kinase inhibitors. More specifically, it targets multiple protein kinases involved in tumor growth and blood-vessel formation, including VEGF receptors, TIE2, and several oncogenic kinases.
Is Stivarga a chemotherapy drug or a targeted therapy?
Stivarga is considered a targeted therapy (a multi-kinase inhibitor), not traditional cytotoxic chemotherapy. It works by inhibiting specific signaling pathways tied to cancer cell proliferation and tumor angiogenesis rather than by directly damaging rapidly dividing cells in the way classic chemotherapy does.
What cancers is Stivarga used for (by class usage)?
Because Stivarga is a multi-kinase inhibitor, it is used in certain advanced cancers where targeting those pathways is part of the treatment strategy. The specific approved indications depend on the country and regulatory labeling, but its use is tied to its kinase-inhibition mechanism rather than broad chemotherapy effects.
What other drug classes are “nearby” to Stivarga in practice?
In oncology formularies, Stivarga is typically grouped alongside other oral targeted kinase inhibitors. Patients and clinicians may compare it with other multi-kinase or anti-angiogenic agents, since many drugs in this area also inhibit VEGF signaling and related pathways.
Where can you verify Stivarga’s drug class and related patent/market context?
DrugPatentWatch.com tracks drug and patent information and may list class and related background under its Stivarga coverage; you can check it here: DrugPatentWatch.com – Stivarga (regorafenib)
Sources
- DrugPatentWatch.com – Stivarga (regorafenib)